| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Skin Neoplasms | 86 | 2024 | 5809 | 4.610 |
Why?
|
| Melanoma | 75 | 2024 | 5694 | 4.450 |
Why?
|
| Nevus, Epithelioid and Spindle Cell | 12 | 2024 | 70 | 3.980 |
Why?
|
| Melanocytes | 16 | 2021 | 509 | 2.220 |
Why?
|
| Nevus, Pigmented | 13 | 2020 | 222 | 2.210 |
Why?
|
| Sentinel Lymph Node Biopsy | 11 | 2016 | 732 | 1.710 |
Why?
|
| Paranasal Sinus Neoplasms | 3 | 2024 | 242 | 1.510 |
Why?
|
| Ubiquitin Thiolesterase | 4 | 2024 | 455 | 1.340 |
Why?
|
| Pathology, Clinical | 7 | 2021 | 376 | 1.220 |
Why?
|
| Lymphatic Metastasis | 16 | 2017 | 2913 | 1.130 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 5 | 2018 | 178 | 1.050 |
Why?
|
| Skin Diseases | 8 | 2021 | 1095 | 1.040 |
Why?
|
| Lymphoma, T-Cell, Cutaneous | 5 | 2021 | 212 | 0.980 |
Why?
|
| Lymphoma, B-Cell | 7 | 2014 | 938 | 0.960 |
Why?
|
| Nasal Mucosa | 2 | 2024 | 413 | 0.900 |
Why?
|
| Dermatology | 9 | 2021 | 918 | 0.890 |
Why?
|
| Nevus | 7 | 2024 | 205 | 0.860 |
Why?
|
| Lymph Nodes | 7 | 2016 | 3461 | 0.860 |
Why?
|
| Neoplasms, Multiple Primary | 3 | 2014 | 592 | 0.840 |
Why?
|
| Tumor Suppressor Proteins | 4 | 2024 | 2803 | 0.820 |
Why?
|
| Neoplasm Proteins | 11 | 2019 | 3594 | 0.780 |
Why?
|
| Pseudolymphoma | 4 | 2014 | 30 | 0.750 |
Why?
|
| S100 Proteins | 3 | 2016 | 216 | 0.700 |
Why?
|
| Immunohistochemistry | 28 | 2024 | 11067 | 0.670 |
Why?
|
| Eye Neoplasms | 2 | 2019 | 307 | 0.650 |
Why?
|
| Skin | 17 | 2021 | 4473 | 0.640 |
Why?
|
| Diagnosis, Differential | 31 | 2024 | 12976 | 0.640 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2021 | 237 | 0.620 |
Why?
|
| Gene Expression Regulation, Neoplastic | 13 | 2020 | 8530 | 0.610 |
Why?
|
| Nephrogenic Fibrosing Dermopathy | 4 | 2016 | 42 | 0.600 |
Why?
|
| Ubiquitin-Conjugating Enzymes | 1 | 2017 | 199 | 0.540 |
Why?
|
| TRPM Cation Channels | 4 | 2016 | 139 | 0.510 |
Why?
|
| Dysplastic Nevus Syndrome | 4 | 2011 | 61 | 0.490 |
Why?
|
| Pathology, Surgical | 4 | 2014 | 151 | 0.470 |
Why?
|
| Mycosis Fungoides | 4 | 2019 | 170 | 0.460 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 2018 | 1405 | 0.420 |
Why?
|
| Biopsy | 18 | 2021 | 6781 | 0.410 |
Why?
|
| BRCA1 Protein | 1 | 2019 | 1149 | 0.410 |
Why?
|
| Antigens, Neoplasm | 5 | 2015 | 1985 | 0.410 |
Why?
|
| Measles | 1 | 2014 | 181 | 0.400 |
Why?
|
| Proto-Oncogene Proteins B-raf | 10 | 2024 | 2054 | 0.400 |
Why?
|
| Antigens, CD1 | 1 | 2014 | 439 | 0.400 |
Why?
|
| Churg-Strauss Syndrome | 2 | 2022 | 75 | 0.370 |
Why?
|
| Syphilis, Cutaneous | 1 | 2010 | 6 | 0.370 |
Why?
|
| Dermis | 2 | 2013 | 202 | 0.360 |
Why?
|
| Keratin-17 | 3 | 2016 | 26 | 0.360 |
Why?
|
| Humans | 154 | 2024 | 761208 | 0.360 |
Why?
|
| Neurosyphilis | 1 | 2010 | 27 | 0.360 |
Why?
|
| Mucinosis, Follicular | 2 | 2000 | 8 | 0.350 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2020 | 1089 | 0.350 |
Why?
|
| Pityriasis Lichenoides | 1 | 2009 | 6 | 0.350 |
Why?
|
| Optic Neuritis | 1 | 2010 | 173 | 0.300 |
Why?
|
| Melanoma-Specific Antigens | 4 | 2016 | 74 | 0.300 |
Why?
|
| Homeodomain Proteins | 1 | 2017 | 2414 | 0.300 |
Why?
|
| Oncogenes | 6 | 2013 | 1220 | 0.290 |
Why?
|
| Membrane Proteins | 6 | 2016 | 7851 | 0.290 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2012 | 746 | 0.280 |
Why?
|
| MART-1 Antigen | 3 | 2016 | 63 | 0.280 |
Why?
|
| Male | 80 | 2024 | 360693 | 0.280 |
Why?
|
| Gadolinium | 2 | 2013 | 961 | 0.280 |
Why?
|
| Adiposis Dolorosa | 1 | 2006 | 11 | 0.270 |
Why?
|
| Erythema Nodosum | 1 | 2006 | 32 | 0.270 |
Why?
|
| Prognosis | 15 | 2024 | 29687 | 0.260 |
Why?
|
| Middle Aged | 64 | 2024 | 220853 | 0.260 |
Why?
|
| Kidney Diseases | 2 | 2011 | 2092 | 0.260 |
Why?
|
| Bartonella henselae | 1 | 2005 | 15 | 0.260 |
Why?
|
| Cat-Scratch Disease | 1 | 2005 | 23 | 0.260 |
Why?
|
| Microphthalmia-Associated Transcription Factor | 5 | 2016 | 258 | 0.260 |
Why?
|
| Granuloma, Foreign-Body | 2 | 2015 | 42 | 0.250 |
Why?
|
| Exanthema | 4 | 2014 | 503 | 0.250 |
Why?
|
| Aged | 50 | 2024 | 169288 | 0.250 |
Why?
|
| Lipomatosis | 1 | 2006 | 112 | 0.250 |
Why?
|
| Female | 85 | 2024 | 392544 | 0.250 |
Why?
|
| Observer Variation | 5 | 2024 | 2610 | 0.250 |
Why?
|
| Adult | 55 | 2024 | 221119 | 0.250 |
Why?
|
| Splenic Neoplasms | 1 | 2005 | 94 | 0.250 |
Why?
|
| Melanoma, Amelanotic | 1 | 2005 | 19 | 0.250 |
Why?
|
| Neoplasm Staging | 6 | 2012 | 11119 | 0.240 |
Why?
|
| Germ-Line Mutation | 3 | 2020 | 1852 | 0.240 |
Why?
|
| Disease Progression | 14 | 2021 | 13511 | 0.240 |
Why?
|
| Carcinoma, Basal Cell | 4 | 2015 | 557 | 0.240 |
Why?
|
| Pregnancy Complications, Neoplastic | 3 | 1999 | 258 | 0.230 |
Why?
|
| Aged, 80 and over | 23 | 2020 | 58952 | 0.220 |
Why?
|
| Skin Ulcer | 2 | 2014 | 130 | 0.220 |
Why?
|
| Transcription Factors | 5 | 2017 | 12099 | 0.210 |
Why?
|
| Dermatomyositis | 1 | 2005 | 258 | 0.200 |
Why?
|
| Inhibitor of Apoptosis Proteins | 3 | 2013 | 198 | 0.200 |
Why?
|
| Pemphigus | 1 | 2003 | 107 | 0.200 |
Why?
|
| Melanosis | 2 | 2021 | 93 | 0.200 |
Why?
|
| Young Adult | 18 | 2020 | 59221 | 0.200 |
Why?
|
| Massachusetts | 7 | 2020 | 8837 | 0.200 |
Why?
|
| Sweet Syndrome | 2 | 2013 | 58 | 0.200 |
Why?
|
| Telepathology | 2 | 2014 | 77 | 0.200 |
Why?
|
| Paraneoplastic Syndromes | 1 | 2003 | 155 | 0.190 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2015 | 4574 | 0.190 |
Why?
|
| Arm | 1 | 2005 | 589 | 0.190 |
Why?
|
| Faculty, Medical | 1 | 2010 | 1205 | 0.190 |
Why?
|
| Eccrine Glands | 2 | 1999 | 52 | 0.190 |
Why?
|
| Immunocompromised Host | 2 | 2012 | 858 | 0.190 |
Why?
|
| Neoplasms, Second Primary | 2 | 2019 | 1052 | 0.190 |
Why?
|
| Adolescent | 20 | 2024 | 88298 | 0.190 |
Why?
|
| Fellowships and Scholarships | 1 | 2010 | 1115 | 0.190 |
Why?
|
| Creatinine | 2 | 2011 | 1897 | 0.190 |
Why?
|
| STAT Transcription Factors | 1 | 2021 | 188 | 0.180 |
Why?
|
| Warfarin | 1 | 2009 | 1482 | 0.180 |
Why?
|
| Hyperplasia | 2 | 2021 | 1150 | 0.180 |
Why?
|
| Janus Kinases | 1 | 2021 | 248 | 0.180 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2024 | 3634 | 0.180 |
Why?
|
| Leukemic Infiltration | 1 | 2000 | 47 | 0.170 |
Why?
|
| Neoplasm Metastasis | 7 | 2021 | 4909 | 0.170 |
Why?
|
| DNA, Neoplasm | 4 | 2009 | 1743 | 0.170 |
Why?
|
| Mitotic Index | 3 | 2014 | 162 | 0.170 |
Why?
|
| Prurigo | 1 | 2020 | 25 | 0.170 |
Why?
|
| Lymphomatoid Papulosis | 2 | 2015 | 16 | 0.170 |
Why?
|
| Remote Consultation | 2 | 2014 | 237 | 0.170 |
Why?
|
| Spleen | 2 | 2005 | 2290 | 0.170 |
Why?
|
| Muir-Torre Syndrome | 1 | 2019 | 12 | 0.160 |
Why?
|
| Lymphoma, T-Cell | 1 | 2021 | 303 | 0.160 |
Why?
|
| Hair Follicle | 1 | 2021 | 211 | 0.160 |
Why?
|
| Follow-Up Studies | 10 | 2017 | 39126 | 0.160 |
Why?
|
| Hyperpigmentation | 1 | 2020 | 116 | 0.160 |
Why?
|
| Child | 15 | 2024 | 80152 | 0.150 |
Why?
|
| Fever | 3 | 2014 | 1618 | 0.150 |
Why?
|
| Antigens | 1 | 2004 | 1441 | 0.150 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 3 | 2013 | 1404 | 0.150 |
Why?
|
| Necrobiosis Lipoidica | 1 | 1997 | 14 | 0.150 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 2 | 2015 | 168 | 0.150 |
Why?
|
| Education, Medical, Graduate | 1 | 2010 | 2374 | 0.150 |
Why?
|
| Lymph Node Excision | 2 | 2015 | 1270 | 0.140 |
Why?
|
| Eosinophilia | 1 | 2022 | 557 | 0.140 |
Why?
|
| Leukemia, Myeloid | 1 | 2000 | 693 | 0.140 |
Why?
|
| Lymphoma, Follicular | 1 | 2001 | 457 | 0.140 |
Why?
|
| Alopecia | 1 | 2021 | 412 | 0.140 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2022 | 1784 | 0.140 |
Why?
|
| Neoplasm Invasiveness | 6 | 2016 | 3590 | 0.130 |
Why?
|
| In Situ Hybridization | 4 | 2009 | 1900 | 0.130 |
Why?
|
| False Negative Reactions | 2 | 2012 | 573 | 0.130 |
Why?
|
| Pancytopenia | 2 | 2014 | 102 | 0.130 |
Why?
|
| Pericytes | 1 | 2019 | 294 | 0.130 |
Why?
|
| Tattooing | 1 | 1996 | 57 | 0.130 |
Why?
|
| Virus Diseases | 2 | 2014 | 716 | 0.130 |
Why?
|
| Histiocytoma, Benign Fibrous | 1 | 1996 | 64 | 0.130 |
Why?
|
| Staphylococcal Protein A | 1 | 1995 | 39 | 0.130 |
Why?
|
| Hutchinson's Melanotic Freckle | 2 | 2009 | 25 | 0.130 |
Why?
|
| Dermatitis, Exfoliative | 1 | 2015 | 27 | 0.130 |
Why?
|
| Lipoma | 2 | 2009 | 293 | 0.130 |
Why?
|
| Actinin | 1 | 1996 | 163 | 0.130 |
Why?
|
| Neoplasms, Basal Cell | 1 | 2015 | 31 | 0.130 |
Why?
|
| Immunosorbent Techniques | 1 | 1995 | 174 | 0.120 |
Why?
|
| Predictive Value of Tests | 6 | 2024 | 15308 | 0.120 |
Why?
|
| Vasculitis, Leukocytoclastic, Cutaneous | 1 | 1995 | 42 | 0.120 |
Why?
|
| Pathology | 1 | 2018 | 269 | 0.120 |
Why?
|
| Mutation | 7 | 2024 | 30002 | 0.120 |
Why?
|
| Biopsy, Needle | 2 | 2010 | 1624 | 0.120 |
Why?
|
| Serpins | 1 | 2016 | 247 | 0.120 |
Why?
|
| Retrospective Studies | 16 | 2020 | 80674 | 0.120 |
Why?
|
| Proteins | 4 | 2013 | 5993 | 0.120 |
Why?
|
| Maxillary Sinus Neoplasms | 1 | 2014 | 39 | 0.120 |
Why?
|
| Vulvitis | 1 | 1993 | 8 | 0.120 |
Why?
|
| Tick-Borne Diseases | 1 | 2014 | 36 | 0.110 |
Why?
|
| Child, Preschool | 8 | 2024 | 42224 | 0.110 |
Why?
|
| Mass Screening | 3 | 2019 | 5426 | 0.110 |
Why?
|
| Carcinoma, Basosquamous | 1 | 2013 | 7 | 0.110 |
Why?
|
| Immunoglobulin G | 3 | 2018 | 4537 | 0.110 |
Why?
|
| Silicones | 1 | 2015 | 228 | 0.110 |
Why?
|
| Fatal Outcome | 4 | 2021 | 1838 | 0.110 |
Why?
|
| Keratin-14 | 1 | 2013 | 56 | 0.110 |
Why?
|
| Coloring Agents | 1 | 1996 | 561 | 0.110 |
Why?
|
| Eczema | 1 | 2016 | 246 | 0.110 |
Why?
|
| Anticoagulants | 1 | 2009 | 4795 | 0.110 |
Why?
|
| Immunoenzyme Techniques | 4 | 2008 | 1703 | 0.110 |
Why?
|
| Nerve Growth Factors | 1 | 2016 | 564 | 0.110 |
Why?
|
| Sarcoma, Myeloid | 1 | 2013 | 52 | 0.110 |
Why?
|
| RNA, Messenger | 3 | 2009 | 12747 | 0.110 |
Why?
|
| DNA Mutational Analysis | 1 | 2021 | 4107 | 0.110 |
Why?
|
| Stomach Neoplasms | 1 | 2003 | 1457 | 0.110 |
Why?
|
| Panniculitis | 3 | 2013 | 45 | 0.100 |
Why?
|
| Substance Abuse, Intravenous | 1 | 1997 | 529 | 0.100 |
Why?
|
| Doxycycline | 1 | 2015 | 344 | 0.100 |
Why?
|
| Carbon | 1 | 1996 | 665 | 0.100 |
Why?
|
| Cosmetic Techniques | 1 | 2015 | 147 | 0.100 |
Why?
|
| Eye Proteins | 1 | 2016 | 632 | 0.100 |
Why?
|
| Granuloma Annulare | 1 | 2013 | 29 | 0.100 |
Why?
|
| Liver Function Tests | 1 | 2014 | 525 | 0.100 |
Why?
|
| Survival Rate | 5 | 2018 | 12728 | 0.100 |
Why?
|
| Herpes Genitalis | 1 | 1993 | 149 | 0.100 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 2 | 2013 | 619 | 0.100 |
Why?
|
| Necrosis | 3 | 2012 | 1610 | 0.100 |
Why?
|
| Antigen Presentation | 1 | 2017 | 1251 | 0.100 |
Why?
|
| Hedgehog Proteins | 1 | 2016 | 769 | 0.100 |
Why?
|
| Integrins | 1 | 1996 | 835 | 0.100 |
Why?
|
| T-Lymphocytes | 2 | 2000 | 10203 | 0.100 |
Why?
|
| Reproducibility of Results | 9 | 2024 | 20119 | 0.100 |
Why?
|
| Cell Count | 2 | 2011 | 1831 | 0.100 |
Why?
|
| Sweat Gland Neoplasms | 2 | 2009 | 116 | 0.100 |
Why?
|
| Gene Regulatory Networks | 1 | 2020 | 1743 | 0.090 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2015 | 531 | 0.090 |
Why?
|
| Caveolin 1 | 1 | 2013 | 255 | 0.090 |
Why?
|
| Fasciitis, Necrotizing | 1 | 2012 | 79 | 0.090 |
Why?
|
| Cytosine | 1 | 2012 | 212 | 0.090 |
Why?
|
| Comparative Genomic Hybridization | 2 | 2010 | 473 | 0.090 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 2 | 2022 | 1624 | 0.090 |
Why?
|
| Onychomycosis | 1 | 2011 | 50 | 0.090 |
Why?
|
| Adenosine Deaminase | 1 | 2013 | 250 | 0.090 |
Why?
|
| Brazil | 1 | 2015 | 1228 | 0.090 |
Why?
|
| Cell Nucleus | 3 | 2010 | 2881 | 0.090 |
Why?
|
| Hand | 1 | 1996 | 902 | 0.090 |
Why?
|
| Mutation, Missense | 1 | 2020 | 2567 | 0.090 |
Why?
|
| Syphilis Serodiagnosis | 1 | 2010 | 37 | 0.090 |
Why?
|
| Diabetes Complications | 1 | 1997 | 1316 | 0.090 |
Why?
|
| Treponema pallidum | 1 | 2010 | 47 | 0.090 |
Why?
|
| Mast Cells | 1 | 1998 | 1392 | 0.090 |
Why?
|
| Interleukin-1 | 2 | 2011 | 1250 | 0.090 |
Why?
|
| Subcutaneous Tissue | 2 | 2012 | 132 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-kit | 2 | 2014 | 726 | 0.090 |
Why?
|
| Oxidative Phosphorylation | 1 | 2012 | 495 | 0.090 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2017 | 5300 | 0.090 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 2 | 2015 | 976 | 0.090 |
Why?
|
| Herpes Zoster | 1 | 2013 | 253 | 0.090 |
Why?
|
| Evidence-Based Medicine | 2 | 2021 | 3691 | 0.090 |
Why?
|
| Antibodies, Monoclonal | 4 | 2017 | 9187 | 0.090 |
Why?
|
| Anus Neoplasms | 1 | 2014 | 330 | 0.090 |
Why?
|
| North America | 1 | 2013 | 1284 | 0.090 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2014 | 4021 | 0.080 |
Why?
|
| Lasers, Dye | 1 | 2009 | 28 | 0.080 |
Why?
|
| Radiography | 2 | 2014 | 6974 | 0.080 |
Why?
|
| Gene Amplification | 5 | 2013 | 1084 | 0.080 |
Why?
|
| Scotoma | 1 | 2010 | 128 | 0.080 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2013 | 630 | 0.080 |
Why?
|
| Adenoma, Sweat Gland | 1 | 2009 | 17 | 0.080 |
Why?
|
| Cell Proliferation | 4 | 2019 | 10422 | 0.080 |
Why?
|
| Down-Regulation | 4 | 2013 | 2916 | 0.080 |
Why?
|
| Receptors, Progesterone | 1 | 1994 | 1129 | 0.080 |
Why?
|
| Drug Eruptions | 1 | 2012 | 335 | 0.080 |
Why?
|
| Guillain-Barre Syndrome | 1 | 2010 | 127 | 0.080 |
Why?
|
| Skin Diseases, Vesiculobullous | 1 | 2009 | 85 | 0.080 |
Why?
|
| Reference Standards | 1 | 2012 | 1005 | 0.080 |
Why?
|
| Glycolysis | 1 | 2012 | 836 | 0.080 |
Why?
|
| Protein Array Analysis | 1 | 2010 | 399 | 0.080 |
Why?
|
| Gene Dosage | 2 | 2010 | 1217 | 0.080 |
Why?
|
| Diagnostic Imaging | 2 | 2014 | 3534 | 0.080 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2013 | 4513 | 0.080 |
Why?
|
| Carcinoma in Situ | 1 | 2014 | 791 | 0.070 |
Why?
|
| Microtubule-Associated Proteins | 2 | 2010 | 1075 | 0.070 |
Why?
|
| Pharyngitis | 1 | 2009 | 220 | 0.070 |
Why?
|
| Dermatitis, Atopic | 1 | 2015 | 731 | 0.070 |
Why?
|
| Antibodies, Neoplasm | 2 | 1999 | 282 | 0.070 |
Why?
|
| Forkhead Transcription Factors | 1 | 2015 | 1613 | 0.070 |
Why?
|
| Incidence | 5 | 2020 | 21365 | 0.070 |
Why?
|
| Hematologic Neoplasms | 1 | 2019 | 1895 | 0.070 |
Why?
|
| Cancer Vaccines | 1 | 2015 | 1038 | 0.070 |
Why?
|
| Diagnostic Errors | 2 | 2012 | 1265 | 0.070 |
Why?
|
| Neoplasm Recurrence, Local | 7 | 2021 | 9278 | 0.070 |
Why?
|
| B-Lymphocytes | 2 | 1999 | 4744 | 0.070 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2013 | 1132 | 0.070 |
Why?
|
| Erythema | 2 | 2006 | 262 | 0.070 |
Why?
|
| Psoriasis | 1 | 2015 | 946 | 0.070 |
Why?
|
| Nose Neoplasms | 1 | 2009 | 249 | 0.070 |
Why?
|
| Specimen Handling | 1 | 2011 | 702 | 0.070 |
Why?
|
| Biological Specimen Banks | 1 | 2012 | 780 | 0.070 |
Why?
|
| Blindness | 1 | 2010 | 585 | 0.070 |
Why?
|
| Neovascularization, Pathologic | 1 | 2016 | 2636 | 0.070 |
Why?
|
| Practice Guidelines as Topic | 3 | 2019 | 7400 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2017 | 6486 | 0.070 |
Why?
|
| RNA, Neoplasm | 1 | 2009 | 748 | 0.070 |
Why?
|
| Gene Expression Profiling | 2 | 2020 | 9416 | 0.070 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 1997 | 1640 | 0.070 |
Why?
|
| Autopsy | 1 | 2009 | 1010 | 0.060 |
Why?
|
| Academic Medical Centers | 2 | 2020 | 2756 | 0.060 |
Why?
|
| Genetic Heterogeneity | 1 | 2009 | 734 | 0.060 |
Why?
|
| Receptors, Estrogen | 1 | 1994 | 2208 | 0.060 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2012 | 4340 | 0.060 |
Why?
|
| Risk Assessment | 4 | 2019 | 24021 | 0.060 |
Why?
|
| Mice, SCID | 4 | 2013 | 2621 | 0.060 |
Why?
|
| Neck | 1 | 2009 | 734 | 0.060 |
Why?
|
| Zoonoses | 1 | 2005 | 179 | 0.060 |
Why?
|
| Combined Modality Therapy | 4 | 2009 | 8519 | 0.060 |
Why?
|
| Data Collection | 1 | 2013 | 3320 | 0.060 |
Why?
|
| Cats | 1 | 2005 | 974 | 0.060 |
Why?
|
| DNA-Binding Proteins | 4 | 2015 | 9566 | 0.060 |
Why?
|
| Herpesvirus 4, Human | 1 | 2009 | 1076 | 0.060 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily B | 1 | 2004 | 84 | 0.060 |
Why?
|
| History, 21st Century | 1 | 2010 | 1567 | 0.060 |
Why?
|
| Lymphatic Diseases | 1 | 2005 | 320 | 0.060 |
Why?
|
| Immunotherapy | 2 | 2020 | 4642 | 0.060 |
Why?
|
| Membrane Glycoproteins | 3 | 2016 | 3696 | 0.060 |
Why?
|
| Blood Chemical Analysis | 1 | 2005 | 436 | 0.060 |
Why?
|
| Neoplasm Transplantation | 3 | 2013 | 2010 | 0.050 |
Why?
|
| Cell Line, Tumor | 7 | 2013 | 16952 | 0.050 |
Why?
|
| Cell Transformation, Neoplastic | 3 | 2013 | 2820 | 0.050 |
Why?
|
| gp100 Melanoma Antigen | 2 | 2016 | 38 | 0.050 |
Why?
|
| Health Care Surveys | 1 | 2010 | 2425 | 0.050 |
Why?
|
| Asthma | 1 | 2022 | 6230 | 0.050 |
Why?
|
| Case Management | 1 | 2005 | 272 | 0.050 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2013 | 1393 | 0.050 |
Why?
|
| Hodgkin Disease | 1 | 2010 | 1379 | 0.050 |
Why?
|
| Boston | 2 | 2012 | 9327 | 0.050 |
Why?
|
| Muscle Weakness | 1 | 2005 | 412 | 0.050 |
Why?
|
| Adenocarcinoma | 2 | 2016 | 6341 | 0.050 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2012 | 1812 | 0.050 |
Why?
|
| Complement C3 | 1 | 2004 | 434 | 0.050 |
Why?
|
| History, 20th Century | 1 | 2010 | 2765 | 0.050 |
Why?
|
| Adenocarcinoma, Follicular | 1 | 2005 | 323 | 0.050 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2014 | 3366 | 0.050 |
Why?
|
| Immunophenotyping | 3 | 2005 | 1867 | 0.050 |
Why?
|
| Pemphigoid, Bullous | 1 | 2003 | 112 | 0.050 |
Why?
|
| Cohort Studies | 6 | 2019 | 41496 | 0.050 |
Why?
|
| Contrast Media | 2 | 2013 | 5311 | 0.050 |
Why?
|
| Edema | 1 | 2005 | 764 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2019 | 17897 | 0.050 |
Why?
|
| Drug Administration Schedule | 1 | 2009 | 4851 | 0.050 |
Why?
|
| Receptors, Complement 3d | 1 | 2001 | 117 | 0.050 |
Why?
|
| Mouth Diseases | 1 | 2003 | 240 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 1 | 2001 | 190 | 0.050 |
Why?
|
| Mouth Mucosa | 1 | 2003 | 432 | 0.040 |
Why?
|
| Lectins, C-Type | 1 | 2004 | 585 | 0.040 |
Why?
|
| Current Procedural Terminology | 1 | 2021 | 89 | 0.040 |
Why?
|
| Skin Diseases, Viral | 1 | 2000 | 26 | 0.040 |
Why?
|
| Aging | 1 | 2019 | 8702 | 0.040 |
Why?
|
| RNA-Binding Proteins | 2 | 2013 | 1855 | 0.040 |
Why?
|
| Melanoma, Experimental | 2 | 2006 | 561 | 0.040 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2009 | 1158 | 0.040 |
Why?
|
| Abdomen | 1 | 2006 | 1128 | 0.040 |
Why?
|
| Eye Diseases | 1 | 2005 | 653 | 0.040 |
Why?
|
| Technetium Tc 99m Sulfur Colloid | 1 | 1999 | 63 | 0.040 |
Why?
|
| Neoplastic Stem Cells | 1 | 2008 | 1348 | 0.040 |
Why?
|
| Fenofibrate | 1 | 2000 | 87 | 0.040 |
Why?
|
| Antigens, Surface | 1 | 2004 | 1607 | 0.040 |
Why?
|
| Gene Fusion | 1 | 2022 | 355 | 0.040 |
Why?
|
| Analgesics | 1 | 2006 | 1068 | 0.040 |
Why?
|
| Consensus | 2 | 2023 | 3134 | 0.040 |
Why?
|
| Carbamazepine | 1 | 2000 | 224 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 3 | 2012 | 6124 | 0.040 |
Why?
|
| Multivariate Analysis | 3 | 2013 | 12052 | 0.040 |
Why?
|
| PTEN Phosphohydrolase | 2 | 2016 | 1111 | 0.040 |
Why?
|
| Referral and Consultation | 1 | 2012 | 3608 | 0.040 |
Why?
|
| Epigenesis, Genetic | 1 | 2012 | 3788 | 0.040 |
Why?
|
| Zinc Fingers | 1 | 2001 | 575 | 0.040 |
Why?
|
| Cell Lineage | 1 | 2008 | 2548 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2015 | 14610 | 0.040 |
Why?
|
| World Health Organization | 1 | 2005 | 1321 | 0.040 |
Why?
|
| Time Factors | 3 | 2014 | 39957 | 0.040 |
Why?
|
| Signal Transduction | 1 | 2021 | 23416 | 0.040 |
Why?
|
| Retinitis | 1 | 1998 | 36 | 0.040 |
Why?
|
| Paranasal Sinuses | 1 | 2021 | 265 | 0.040 |
Why?
|
| Epidermis | 3 | 2014 | 526 | 0.040 |
Why?
|
| Neprilysin | 1 | 2001 | 478 | 0.040 |
Why?
|
| Interleukin-3 | 1 | 1999 | 425 | 0.040 |
Why?
|
| Borrelia Infections | 1 | 1997 | 17 | 0.040 |
Why?
|
| Risk Factors | 6 | 2019 | 74239 | 0.040 |
Why?
|
| Treatment Outcome | 5 | 2015 | 64681 | 0.040 |
Why?
|
| Health Facilities | 1 | 2023 | 575 | 0.040 |
Why?
|
| Borrelia burgdorferi Group | 1 | 1997 | 97 | 0.040 |
Why?
|
| Cell Division | 3 | 2008 | 4451 | 0.040 |
Why?
|
| Injections, Subcutaneous | 2 | 2015 | 672 | 0.040 |
Why?
|
| Mucous Membrane | 1 | 2021 | 659 | 0.040 |
Why?
|
| Abnormalities, Multiple | 1 | 2005 | 1423 | 0.040 |
Why?
|
| Phosphoproteins | 1 | 2006 | 2444 | 0.040 |
Why?
|
| MicroRNAs | 1 | 2013 | 3758 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2009 | 10756 | 0.040 |
Why?
|
| United States | 5 | 2021 | 72339 | 0.040 |
Why?
|
| Genome, Human | 1 | 2010 | 4423 | 0.030 |
Why?
|
| Receptors, Collagen | 1 | 1996 | 25 | 0.030 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2013 | 3609 | 0.030 |
Why?
|
| X-Ray Diffraction | 1 | 1997 | 418 | 0.030 |
Why?
|
| beta 2-Microglobulin | 1 | 2017 | 329 | 0.030 |
Why?
|
| Attitude of Health Personnel | 1 | 2010 | 3885 | 0.030 |
Why?
|
| Disease-Free Survival | 2 | 2017 | 6819 | 0.030 |
Why?
|
| Silicon Dioxide | 1 | 1997 | 216 | 0.030 |
Why?
|
| Catheters, Indwelling | 1 | 1999 | 426 | 0.030 |
Why?
|
| Mice, Inbred NOD | 2 | 2013 | 1822 | 0.030 |
Why?
|
| Keloid | 1 | 2016 | 55 | 0.030 |
Why?
|
| Tissue Array Analysis | 2 | 2008 | 550 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2015 | 7407 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2013 | 15920 | 0.030 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 1999 | 890 | 0.030 |
Why?
|
| Microscopy, Fluorescence | 2 | 2013 | 2635 | 0.030 |
Why?
|
| Cicatrix, Hypertrophic | 1 | 2016 | 80 | 0.030 |
Why?
|
| Homocysteine | 1 | 1999 | 637 | 0.030 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2006 | 2897 | 0.030 |
Why?
|
| Lung | 1 | 2014 | 9979 | 0.030 |
Why?
|
| Histocytochemistry | 1 | 2016 | 697 | 0.030 |
Why?
|
| Purpura, Thrombocytopenic | 1 | 1995 | 42 | 0.030 |
Why?
|
| Medical Records | 1 | 2001 | 1409 | 0.030 |
Why?
|
| Early Detection of Cancer | 2 | 2020 | 3198 | 0.030 |
Why?
|
| Hypolipidemic Agents | 1 | 2000 | 609 | 0.030 |
Why?
|
| Animals | 11 | 2017 | 168079 | 0.030 |
Why?
|
| Loss of Heterozygosity | 1 | 2017 | 662 | 0.030 |
Why?
|
| Plasma Cells | 1 | 1999 | 597 | 0.030 |
Why?
|
| Radionuclide Imaging | 1 | 1999 | 1989 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 1999 | 1597 | 0.030 |
Why?
|
| Buttocks | 1 | 2015 | 112 | 0.030 |
Why?
|
| GATA3 Transcription Factor | 1 | 2015 | 155 | 0.030 |
Why?
|
| Lymphedema | 1 | 2001 | 523 | 0.030 |
Why?
|
| Proportional Hazards Models | 2 | 2017 | 12474 | 0.030 |
Why?
|
| Adipose Tissue | 1 | 2006 | 3313 | 0.030 |
Why?
|
| Uveitis | 1 | 1998 | 396 | 0.030 |
Why?
|
| Receptors, Tumor Necrosis Factor | 2 | 2012 | 585 | 0.030 |
Why?
|
| Neutropenia | 1 | 1999 | 885 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2019 | 2277 | 0.030 |
Why?
|
| SEER Program | 1 | 2019 | 1453 | 0.030 |
Why?
|
| Vesicular Transport Proteins | 1 | 2016 | 374 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2022 | 2011 | 0.030 |
Why?
|
| Reference Values | 1 | 2001 | 4921 | 0.030 |
Why?
|
| Lymphoma | 1 | 2003 | 1898 | 0.030 |
Why?
|
| Vulva | 1 | 1993 | 84 | 0.030 |
Why?
|
| Purkinje Cells | 1 | 1995 | 226 | 0.030 |
Why?
|
| Mice | 8 | 2013 | 81326 | 0.030 |
Why?
|
| Digestive System Neoplasms | 1 | 2013 | 83 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2016 | 697 | 0.030 |
Why?
|
| Oxidative Phosphorylation Coupling Factors | 1 | 2012 | 1 | 0.030 |
Why?
|
| Maxillary Sinus | 1 | 2014 | 176 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2013 | 3777 | 0.030 |
Why?
|
| Lymphocyte Count | 1 | 2015 | 781 | 0.030 |
Why?
|
| GTP Phosphohydrolases | 1 | 2016 | 517 | 0.030 |
Why?
|
| Adenosine Diphosphate | 1 | 1994 | 422 | 0.030 |
Why?
|
| Sigma Factor | 1 | 1994 | 176 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2020 | 4567 | 0.030 |
Why?
|
| Ataxia | 1 | 1995 | 305 | 0.030 |
Why?
|
| Scleroderma, Systemic | 1 | 2016 | 345 | 0.030 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2021 | 1605 | 0.030 |
Why?
|
| Risk | 1 | 2005 | 9616 | 0.030 |
Why?
|
| Metaplasia | 1 | 2013 | 324 | 0.030 |
Why?
|
| T-Box Domain Proteins | 1 | 2015 | 469 | 0.030 |
Why?
|
| Statistics as Topic | 1 | 1999 | 2359 | 0.030 |
Why?
|
| Monocarboxylic Acid Transporters | 1 | 2012 | 80 | 0.030 |
Why?
|
| Histiocytes | 1 | 2013 | 98 | 0.030 |
Why?
|
| Mitochondrial Proton-Translocating ATPases | 1 | 2012 | 53 | 0.030 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 1 | 2013 | 185 | 0.030 |
Why?
|
| Glomerular Filtration Rate | 1 | 2001 | 2182 | 0.030 |
Why?
|
| Mice, Nude | 2 | 2010 | 3605 | 0.030 |
Why?
|
| Giant Cells | 1 | 2013 | 188 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2013 | 410 | 0.030 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2018 | 788 | 0.030 |
Why?
|
| Adenocarcinoma, Clear Cell | 1 | 1994 | 217 | 0.030 |
Why?
|
| Neoplasms, Experimental | 1 | 2017 | 1225 | 0.030 |
Why?
|
| Point Mutation | 1 | 2017 | 1593 | 0.030 |
Why?
|
| Base Sequence | 2 | 2006 | 12404 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2005 | 5969 | 0.020 |
Why?
|
| Pregnancy Proteins | 1 | 2013 | 223 | 0.020 |
Why?
|
| 5-Methylcytosine | 1 | 2012 | 148 | 0.020 |
Why?
|
| RNA | 1 | 2022 | 2709 | 0.020 |
Why?
|
| Minor Histocompatibility Antigens | 1 | 2013 | 294 | 0.020 |
Why?
|
| Thyroid Neoplasms | 1 | 2005 | 2330 | 0.020 |
Why?
|
| RNA Editing | 1 | 2013 | 149 | 0.020 |
Why?
|
| Sodium Hydroxide | 1 | 2011 | 37 | 0.020 |
Why?
|
| Cell Line, Transformed | 1 | 2013 | 864 | 0.020 |
Why?
|
| RNA Interference | 2 | 2013 | 2816 | 0.020 |
Why?
|
| Thrombocytopenia | 1 | 1999 | 1182 | 0.020 |
Why?
|
| beta Catenin | 1 | 2016 | 1042 | 0.020 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2012 | 410 | 0.020 |
Why?
|
| Immunization | 1 | 1996 | 1218 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2009 | 15841 | 0.020 |
Why?
|
| Codon | 1 | 2013 | 597 | 0.020 |
Why?
|
| Hamartoma | 2 | 2009 | 236 | 0.020 |
Why?
|
| Ribonuclease III | 1 | 2013 | 267 | 0.020 |
Why?
|
| Pain | 1 | 2006 | 5072 | 0.020 |
Why?
|
| Software | 2 | 2014 | 4431 | 0.020 |
Why?
|
| Phenotype | 4 | 2015 | 16575 | 0.020 |
Why?
|
| STAT3 Transcription Factor | 1 | 2015 | 872 | 0.020 |
Why?
|
| Bacillus subtilis | 1 | 1994 | 351 | 0.020 |
Why?
|
| Precancerous Conditions | 1 | 1998 | 982 | 0.020 |
Why?
|
| Cicatrix | 1 | 2016 | 793 | 0.020 |
Why?
|
| Australia | 1 | 2014 | 1246 | 0.020 |
Why?
|
| Transplantation, Heterologous | 2 | 2010 | 2381 | 0.020 |
Why?
|
| Introns | 1 | 2013 | 968 | 0.020 |
Why?
|
| Muscle, Skeletal | 1 | 2005 | 4947 | 0.020 |
Why?
|
| Kidney Transplantation | 1 | 2005 | 4242 | 0.020 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2013 | 380 | 0.020 |
Why?
|
| Molecular Targeted Therapy | 1 | 2021 | 2813 | 0.020 |
Why?
|
| Chromosome Aberrations | 2 | 2013 | 1767 | 0.020 |
Why?
|
| Th1 Cells | 1 | 2015 | 1042 | 0.020 |
Why?
|
| Dioxygenases | 1 | 2012 | 346 | 0.020 |
Why?
|
| Prevalence | 2 | 2011 | 15721 | 0.020 |
Why?
|
| T-Lymphocyte Subsets | 1 | 1998 | 1803 | 0.020 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2013 | 495 | 0.020 |
Why?
|
| Th2 Cells | 1 | 2015 | 1071 | 0.020 |
Why?
|
| Carcinoma | 1 | 2001 | 2330 | 0.020 |
Why?
|
| Workflow | 1 | 2014 | 850 | 0.020 |
Why?
|
| Radiopharmaceuticals | 1 | 1999 | 2683 | 0.020 |
Why?
|
| Nerve Tissue Proteins | 1 | 2022 | 4404 | 0.020 |
Why?
|
| Microscopy | 1 | 2014 | 904 | 0.020 |
Why?
|
| Debridement | 1 | 2012 | 493 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2021 | 3923 | 0.020 |
Why?
|
| Renal Dialysis | 1 | 1999 | 1796 | 0.020 |
Why?
|
| Case-Control Studies | 2 | 2020 | 22174 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 1999 | 2691 | 0.020 |
Why?
|
| Mitosis | 1 | 2014 | 1186 | 0.020 |
Why?
|
| Microfilament Proteins | 1 | 1994 | 1130 | 0.020 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 1996 | 1372 | 0.020 |
Why?
|
| Terminology as Topic | 1 | 2016 | 1528 | 0.020 |
Why?
|
| Th17 Cells | 1 | 2015 | 794 | 0.020 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2016 | 1746 | 0.020 |
Why?
|
| Cell Movement | 2 | 2016 | 5195 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2001 | 10088 | 0.020 |
Why?
|
| Eye | 1 | 2012 | 713 | 0.020 |
Why?
|
| Isoenzymes | 1 | 2012 | 1682 | 0.020 |
Why?
|
| Adenosine Triphosphate | 1 | 1994 | 1988 | 0.020 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 1989 | 355 | 0.020 |
Why?
|
| Mice, Knockout | 2 | 2017 | 14392 | 0.020 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2008 | 425 | 0.020 |
Why?
|
| Inflammation | 2 | 2011 | 10759 | 0.020 |
Why?
|
| Kidney Failure, Chronic | 1 | 2000 | 2478 | 0.020 |
Why?
|
| Cadherins | 1 | 2012 | 902 | 0.020 |
Why?
|
| Genes, ras | 1 | 2010 | 654 | 0.020 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2012 | 736 | 0.020 |
Why?
|
| Apoptosis | 2 | 2013 | 9477 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2013 | 3418 | 0.020 |
Why?
|
| Ki-67 Antigen | 1 | 2009 | 628 | 0.020 |
Why?
|
| Autoantibodies | 1 | 1995 | 2119 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 1998 | 13402 | 0.020 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2012 | 937 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2009 | 20588 | 0.020 |
Why?
|
| Focal Adhesion Kinase 1 | 1 | 2006 | 120 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2013 | 3603 | 0.020 |
Why?
|
| Infant, Newborn | 2 | 2005 | 26199 | 0.020 |
Why?
|
| Autoimmune Diseases | 1 | 1998 | 2244 | 0.020 |
Why?
|
| Fibrosis | 1 | 2013 | 2051 | 0.020 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2013 | 1651 | 0.020 |
Why?
|
| Kidney | 1 | 2001 | 7033 | 0.020 |
Why?
|
| Antigen-Presenting Cells | 1 | 1989 | 965 | 0.020 |
Why?
|
| Sex Factors | 1 | 2019 | 10553 | 0.020 |
Why?
|
| Endothelium, Vascular | 1 | 1997 | 4420 | 0.020 |
Why?
|
| Extracellular Matrix | 1 | 2013 | 1720 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 1998 | 17598 | 0.020 |
Why?
|
| Gene Rearrangement | 1 | 2010 | 1125 | 0.020 |
Why?
|
| Antineoplastic Agents | 2 | 2021 | 13632 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2020 | 14675 | 0.020 |
Why?
|
| Pregnancy | 3 | 1999 | 29893 | 0.020 |
Why?
|
| Binding Sites | 1 | 2013 | 5988 | 0.010 |
Why?
|
| Prospective Studies | 3 | 2005 | 54435 | 0.010 |
Why?
|
| Pedigree | 1 | 2012 | 4537 | 0.010 |
Why?
|
| Neoplasm, Residual | 1 | 2009 | 1008 | 0.010 |
Why?
|
| Muscles | 1 | 2009 | 1568 | 0.010 |
Why?
|
| RNA, Small Interfering | 1 | 2013 | 3412 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2014 | 5250 | 0.010 |
Why?
|
| Transfection | 1 | 2011 | 5748 | 0.010 |
Why?
|
| Down Syndrome | 1 | 1991 | 901 | 0.010 |
Why?
|
| Tumor Burden | 1 | 2009 | 1892 | 0.010 |
Why?
|
| Thromboembolism | 1 | 2009 | 992 | 0.010 |
Why?
|
| Liver Diseases | 1 | 1991 | 1301 | 0.010 |
Why?
|
| Poly(A)-Binding Proteins | 1 | 2003 | 35 | 0.010 |
Why?
|
| Breast Neoplasms | 2 | 2001 | 20982 | 0.010 |
Why?
|
| Antigens, CD | 1 | 2013 | 4009 | 0.010 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2012 | 1878 | 0.010 |
Why?
|
| Cross-Sectional Studies | 2 | 2001 | 26071 | 0.010 |
Why?
|
| Gene Deletion | 1 | 2010 | 2658 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2013 | 3702 | 0.010 |
Why?
|
| Genomics | 2 | 2010 | 5828 | 0.010 |
Why?
|
| Interleukin-2 | 1 | 1989 | 1891 | 0.010 |
Why?
|
| Species Specificity | 1 | 2006 | 2406 | 0.010 |
Why?
|
| Cell Survival | 1 | 2011 | 5778 | 0.010 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 1 | 2003 | 125 | 0.010 |
Why?
|
| Acute Disease | 1 | 2012 | 7226 | 0.010 |
Why?
|
| Age Factors | 1 | 2018 | 18384 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2010 | 4111 | 0.010 |
Why?
|
| Bacterial Proteins | 1 | 1994 | 3836 | 0.010 |
Why?
|
| Models, Genetic | 1 | 2010 | 3430 | 0.010 |
Why?
|
| Models, Biological | 2 | 2013 | 9457 | 0.010 |
Why?
|
| Quality Improvement | 1 | 2014 | 3808 | 0.010 |
Why?
|
| Head and Neck Neoplasms | 1 | 2013 | 2894 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2017 | 22127 | 0.010 |
Why?
|
| Cause of Death | 1 | 2009 | 3688 | 0.010 |
Why?
|
| DNA Methylation | 1 | 2013 | 4384 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2008 | 6199 | 0.010 |
Why?
|
| Nuclear Proteins | 1 | 2013 | 5782 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 1999 | 11733 | 0.010 |
Why?
|
| Histones | 1 | 2009 | 2570 | 0.010 |
Why?
|
| Receptor, erbB-2 | 1 | 2009 | 2553 | 0.010 |
Why?
|
| Neoadjuvant Therapy | 1 | 2009 | 2827 | 0.010 |
Why?
|
| Databases, Factual | 1 | 2013 | 7966 | 0.010 |
Why?
|
| Pneumonia | 1 | 2009 | 2142 | 0.010 |
Why?
|
| Anterior Chamber | 1 | 1998 | 194 | 0.010 |
Why?
|
| Rats, Inbred Lew | 1 | 1998 | 1159 | 0.010 |
Why?
|
| Neutralization Tests | 1 | 1998 | 725 | 0.010 |
Why?
|
| Arteriovenous Shunt, Surgical | 1 | 1999 | 290 | 0.010 |
Why?
|
| Nevus, Intradermal | 1 | 1995 | 1 | 0.010 |
Why?
|
| Double-Blind Method | 2 | 2000 | 12341 | 0.010 |
Why?
|
| Placebos | 1 | 2000 | 1666 | 0.010 |
Why?
|
| Gonadal Steroid Hormones | 1 | 1999 | 702 | 0.010 |
Why?
|
| Intraoperative Care | 1 | 1999 | 767 | 0.010 |
Why?
|
| Online Systems | 1 | 1996 | 182 | 0.010 |
Why?
|
| Hyperlipidemias | 1 | 2000 | 771 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 1999 | 2217 | 0.010 |
Why?
|
| Immunization Schedule | 1 | 1996 | 227 | 0.010 |
Why?
|
| Fluorouracil | 1 | 1999 | 1642 | 0.010 |
Why?
|
| Interleukin-4 | 1 | 1998 | 1154 | 0.010 |
Why?
|
| Computer Systems | 1 | 1996 | 470 | 0.010 |
Why?
|
| Time | 1 | 1996 | 545 | 0.010 |
Why?
|
| Killer Cells, Natural | 1 | 2003 | 2194 | 0.010 |
Why?
|
| Cyclophosphamide | 1 | 1999 | 2219 | 0.010 |
Why?
|
| Spores, Bacterial | 1 | 1994 | 113 | 0.010 |
Why?
|
| Chromosome Banding | 1 | 1993 | 260 | 0.010 |
Why?
|
| Gene Expression | 1 | 2006 | 7571 | 0.010 |
Why?
|
| Vimentin | 1 | 1994 | 255 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2012 | 12676 | 0.010 |
Why?
|
| Doxorubicin | 1 | 1999 | 2224 | 0.010 |
Why?
|
| Carcinoembryonic Antigen | 1 | 1994 | 335 | 0.010 |
Why?
|
| Keratins | 1 | 1994 | 498 | 0.010 |
Why?
|
| Parathyroid Hormone-Related Protein | 1 | 1993 | 327 | 0.010 |
Why?
|
| Karyotyping | 1 | 1993 | 1172 | 0.010 |
Why?
|
| Infant | 1 | 2013 | 36169 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2008 | 8998 | 0.010 |
Why?
|
| Cross-Linking Reagents | 1 | 1994 | 684 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 1999 | 3726 | 0.010 |
Why?
|
| Immunoconjugates | 1 | 1998 | 963 | 0.010 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2003 | 4372 | 0.010 |
Why?
|
| Hematopoiesis | 1 | 1999 | 2046 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 1998 | 3155 | 0.010 |
Why?
|
| Cytoplasm | 1 | 1994 | 1498 | 0.010 |
Why?
|
| Epithelium | 1 | 1994 | 1603 | 0.010 |
Why?
|
| Mucin-1 | 1 | 1994 | 538 | 0.010 |
Why?
|
| Cell Fractionation | 1 | 1989 | 248 | 0.000 |
Why?
|
| Lung Neoplasms | 1 | 1993 | 13385 | 0.000 |
Why?
|
| Lipids | 1 | 2000 | 3331 | 0.000 |
Why?
|
| Mice, Inbred CBA | 1 | 1989 | 438 | 0.000 |
Why?
|
| Gene Expression Regulation, Bacterial | 1 | 1994 | 1131 | 0.000 |
Why?
|
| Mice, Inbred C3H | 1 | 1989 | 914 | 0.000 |
Why?
|
| Nucleic Acid Hybridization | 1 | 1989 | 1301 | 0.000 |
Why?
|
| Culture Media | 1 | 1989 | 894 | 0.000 |
Why?
|
| Lymphokines | 1 | 1989 | 925 | 0.000 |
Why?
|
| Research Design | 1 | 1999 | 6180 | 0.000 |
Why?
|
| Drug Combinations | 1 | 1989 | 2048 | 0.000 |
Why?
|
| Phosphorylation | 1 | 1994 | 8300 | 0.000 |
Why?
|
| Promoter Regions, Genetic | 1 | 1994 | 5773 | 0.000 |
Why?
|
| Rats | 1 | 1998 | 23704 | 0.000 |
Why?
|
| Protein Binding | 1 | 1994 | 9297 | 0.000 |
Why?
|
| Transcription, Genetic | 1 | 1994 | 7571 | 0.000 |
Why?
|